Kornimate/medical-research-clean huggingface dataset:
effects of using decision cycle for person-centered glycemic management in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: decision cycle for person-centered glycemic management is a new diabetes decision making .it is defined as a purposefully designed holistic care intervention .the goal is to improve the self-care behavior of patients with type 2 diabetes, thereby improving glycated hemoglobin levels and delaying the occurrence of complications.

the "decision cycle for person-centered glycemic management" jointly proposed by the american diabetes association (ada) and the european association for the study of diabetes (easd) in 2018 , which develops treatment goals and plans based on the patient's personal preferences, values, and goals. participants will be divided into two groups(treatment group 、control group).treatment group will accept the "decision cycle for person-centered glycemic management " .it is a person-centered diabetes decision making. control group will accept the traditional diabetes self-management education. it content focuses more on teaching relevant knowledge and some skills.it is a educator-centered approach. baseline / pre-intervention test (after signing informed consent form) post-intervention test (after finishing intervention) researchers will compare treatment group and control group to see if treatment group has better performance on self-care behaviors and glycated hemoglobin levels .

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with type 2 diabetes by a physician. 2. age: 18 years or above. 3. glycated hemoglobin (hba1c ) test value: 7.5-9.0 % 4. no diabetic oral medications, insulin and glucagon-like peptide-1 were replaced in the outpatient when the case was admitted. 5. no pregnancy during the study period. 6. after the researcher explains the purpose of the research, the research subjects agree to join this researcher. 7. those who are conscious and able to take care of themselves. 8. there is no diagnostic certificate from the american psychiatric association's diagnostic manual of mental disorders, fourth edition (dsm-iv)of all mental illnesses. 9. those who can communicate in mandarin and taiwanese. exclusion criteria: 1. patients diagnosed with type 1 diabetes by a physician. 2. age: under 18 years old. 3. glycated hemoglobin test value: less than 7.5 % and greater than 9.0 % 4. those who replaced oral diabetes medications, insulin and glucagon-like peptide- 1 at the outpatient at the time of admission. 5. pregnancy during the study period. 6. those who are unable to take care of themselves and express themselves.

Keywords: decision cycle for person-centered glycemic management self-care behaviors type 2 diabetes
a study comparing two topicals in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: a randomized, evaluator-blinded, bilateral comparison study to evaluate the safety and efficacy of two topicals in the treatment of subjects with acne vulgaris (study fx2018-23).

a randomized, evaluator-blinded, bilateral comparison study to evaluate the safety and efficacy of two topicals in the treatment of subjects with acne vulgaris. eligible subjects will be randomized (1:1) to treatment with test article a to one side of the face versus test article b on the contralateral side.

Eligibility criteria:
inclusion criteria: * has facial acne vulgaris with: 16 inflammatory lesions (papules, pustules) the inflammatory lesion count on the right and left side of the face should be similar iga score of moderate (3) on both the right and left side of the face exclusion criteria: * acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations. * more than two facial nodules/cysts * sunburn on the face
a study of rd14-01 in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: this study will evaluate the safety and tolerability of rd14-01, a ror1-targeted car t-cell therapy, in patients with ror1+ advanced solid tumors.

this single-arm, open-label, dose-escalation and dose-expansion study will evaluate the safety and tolerability of rd14-01, ror1-targeting car t cells, in adults with ror1+ advanced solid tumors.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old and \< 70 years old, gender unlimited; 2. patients with locally advanced or metastatic solid tumors confirmed by histopathology or cytology; 3. subjects who failed or were intolerant to standard treatment, or lacked effective treatment; 4. ror1+ by central laboratory immunohistochemistry (ihc); 5. adequate organ and marrow function; 6. at least one measurable lesion as per recist v1.1; 7. estimated survival ≥3 months; 7.eastern cooperative oncology group (ecog) performance status 0 or 1; 8.ability to understand and provide informed consent. exclusion criteria: 1. prior treatment with any agent targeting ror1; 2. received anti-tumor therapy within 4 weeks prior to the start of treatment, including chemotherapy, radiotherapy, targeted therapy, etc. (excluding preconditioning); 3. presence of active central nervous system (cns) metastasis; 4. there is or has been a history of severe cardiovascular disease; 5. there is an uncontrolled pleural, abdominal or pericardial effusion 6. hiv-positive, active acute or chronic hbv or hcv, or active tuberculosis; 7. pregnant or breast-feeding females; 8. there is a known or suspected failure to comply with the study protocol (for example, alcohol abuse, drug dependence, or psychological disorders) or any condition that the investigator believes may increase the subjects' risk or interfere with the results of the test.

Keywords: solid tumor car-t cell ror1
new international cteph database

Conditions: Chronic Thromboembolic Pulmonary Hypertension; CTEPH

Summary: the new international cteph database is a prospective, observational multi-center disease registry run by the international cteph association (ica), which will collect data in chronic thromboembolic pulmonary hypertension (cteph) patients worldwide. the registry will run for approximately 5 years. its objective is to provide an overview on epidemiology of cteph, mode of diagnosis and treatment approaches worldwide as well as determinants of long-term outcomes as measured by new york heart association (nyha) functional class and survival. the data collected will improve the knowledge and understanding of this condition, support the further development of diagnosis and treatment guidelines for patients with cteph, and contribute to improving patient care in the long-term.


Eligibility criteria:
inclusion criteria: * patients must be newly diagnosed with chronic thromboembolic pulmonary hypertension (cteph) (incident patients) * patients must have been treated with anti-coagulation for at least 3 months before diagnosis of cteph * patients must be willing to provide informed consent * patients must meet the following criteria for cteph: * mean pulmonary artery pressure (pap) ≥ 25 mmhg at rest * abnormal vq scan, pulmonary angiogram, computed tomography (ct) pulmonary angiogram, or magnetic resonance (mr) pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines exclusion criteria: * none specified

Keywords: cteph balloon pulmonary angioplasty chronic thromboembolic pulmonary hypertension pulmonary endarterectomy bpa pea
liothyronine (t3) for bipolar depression

Conditions: Depression; Bipolar Disorder

Summary: this study evaluates the efficacy of the thyroid hormone t3 for depression in patients with bipolar disorder. in this study patients will be randomized to receive t3 or placebo.

bipolar affective disorder is a debilitating illness, and is characterized by depression episodes that dominates the longitudinal course and are most difficult to treat. controlled trials with monotherapy mood stabilizers such as lithium and valproate show little to no efficacy and antidepressants may offer no additional efficacy. recently there has been a growing interest in the use of quetiapine in bipolar depression. however, a successful treatment may take up to 8 weeks, and full remission is achieved in only 50% of patients. thyroid hormone augmentation strategies have been used in unipolar depression with good results, but there is a paucity of its efficacy in bipolar depression (bd). to our knowledge there are no controlled studies regarding the efficacy of thyroid augmentation in bd. the present study proposes to evaluate the efficacy of t3 as an augmentation to treatment as usual in the treatment of bd. we plan to enroll patients with bipolar disorder i or ii who are currently presenting with depressive symptoms. patients will be randomized to 2 groups - liothyronine or placebo results will provide information on the possible role of thyroid hormone augmentation in the treatment of patients with bipolar depression, and may contribute to alleviate the burden of this disabling condition.

Eligibility criteria:
inclusion criteria: 1. age 18-65; 2. dsm-iv diagnosis of bp i or bp ii as per scid; 3. currently presenting with at least moderate levels of depression (ham-d \> 15; 4. patient has to be on stable dose of at least one mood stabilizer (lithium, valproate, carbamazepine, lamotrigine, second generation antipsychotics) for at least 4 weeks as per history; 5. antidepressants and/or additional mood stabilizers are allowed, but dose should be stable for at least 2 weeks; exclusion criteria: 1. evidence of acute mania or hypomania (as measured by cars-m \> 7); 2. abnormal (outside of lab normal range) thyroid function tests; 3. current thyroid hormone treatment; 4. any medical condition considered a contraindication for treatment with t3 (i.e. history of myocardial infarction, cardiac arrhythmia, severe cardiac insufficiency, autoimmune thyroid disease /hashimoto's thyroiditis as determined by anti-thyroid antibody testing, previous or current thyroid adenoma, hyperthyroidism); 5. ekg showing rhythm other than sinus or repolarization phase abnormalities; 6. current alcohol or substance abuse or dependence in past month as per scid; 7. score of 3 or more on the suicide item of the ham-d; 8. females who are pregnant, breastfeeding, or of childbearing age and not using adequate birth control.

Keywords: bipolar disorder depression treatment randomized controlled trial
the effect of music applied during chemotherapy on anxiety, nausea and satisfaction levels

Conditions: Anxiety; Chemotherapy Effect; Satisfaction, Patient; Cancer; Nursing Caries

Summary: chemotherapy is a treatment that uses natural or synthetic chemicals and biological agents to kill rapidly proliferating cells. as chemotherapeutic drugs prevent the growth and proliferation of cancer cells, they also inhibit the growth of normal cells such as intestinal and oral mucosal epithelium, bone marrow cells, and hair follicle cells. during chemotherapy treatment, which is widely used in the treatment of cancer cases and considered one of the most effective methods of cancer treatment, individuals; may experience side effects such as nausea-vomiting, loss of appetite, mouth ulcers, pain, fatigue, anxiety, depression, sleep problems, and changes in their skin and nails. there are several factors that can trigger anxiety in cancer patients: fear of cancer and its treatment-related side effects, fear of relapse after treatment, uncertainty, concerns about changing roles and relationships, and fear of death. treatment methods are available for a variety of side effects and negative effects experienced by cancer patients. these methods include pharmacological and nonpharmacological approaches. for example, benzodiazepines are frequently used to treat anxiety in cancer patients. if benzodiazepines are not adequate, low-dose antipsychotics can be used. however, benzodiazepines and their derivatives may reduce respiratory function, induce sedation, and cause confusion. music is an example of non-pharmacological cognitive-behavioral treatment that is used to control negative symptoms in many fields. the use of music for healing is easy, has no side effects, and is beneficial for physical, psychological, emotional, and spiritual well-being. anxiety and fear can be reduced by therapeutic music, which increases endorphin secretion and positive emotions. treatment of serious illnesses such as cancer requires a holistic approach that includes psychological, social, and spiritual support in addition to pharmacological treatment. therefore, the purpose of this study is to examine how different types of music affect cancer patients' anxiety and satisfaction during chemotherapy.


Eligibility criteria:
inclusion criteria: * \> 18 years old, * receiving chemotherapy for the first time. exclusion criteria: * hearing or vision problems, * have a lower education level than secondary school (the stai is appropriate for those who have at least a sixth-grade reading level), * diagnosed with psychiatric and neurological diseases, * diagnosed with dementia, * received chemotherapy treatment more than once, * planned to receive radiotherapy treatment together with chemotherapy.

Keywords: music chemotherapy nursing anxiety
inferior turbinate surgery in rhinoseptoplasty: a randomized clinical trial with quality of life outcomes

Conditions: Nasal Obstruction; Rhinoplasty; Rhinoseptoplasty; Turbinate Surgery; Quality of Life

Summary: the purpose of this study is to determine whether inferior turbinate surgery during rhinoseptoplasty is effective in improving quality of life and acoustic rhinometry outcomes.


Eligibility criteria:
inclusion criteria: * older than 15 years old; * nasal obstruction and nasal aesthetics complaints; exclusion criteria: * previous septoplasty, turbinates intervention and/or rhinoplasty; * association of other surgical procedures in the same surgical time, as functional endoscopic sinus surgery, blepharoplasty, mentoplasty or otoplasty; * inferior turbinate hypertrophy as the isolated cause of nasal obstruction (no septum deviation or internal valve collapse)

Keywords: nasal obstruction rhinoplasty turbinate surgery quality of life acoustic rhinometry
utilizing helpline for opioid dependence treatment

Conditions: Opioid Dependence

Summary: the investigator propose to develop an opioid telephone helpline, where trained counselors and educators provide referral, educational and targeted interventions and support to individuals interested in addressing their addiction or needing help with managing their pain. the proposed application builds on "tobacco quit line" efforts, a nationally-adopted telephone-based service, providing education materials, access to cessation medication and counseling against tobacco use. similar to tobacco quit line; the proposed telephone based services will remove barriers to treatment as they help individuals at the exact time of need. the helpline will also educate individuals with new onset pain about pain expectations, relaxation techniques, use of pharmacology and psychotherapy for treatment in addition to providing support for coping and reducing dependency on prescription opioids. it will be a low cost, easily accessible and utilizable technology to augment the clinical outcome of medication assisted treatment of opioid use disorder and pain management.

the proposed specific aims are to: 1. test if the helpline is a resourceful tool for patients with opioid use disorder looking for referrals and support to access treatment. the opioid helpline will provide individuals with opioid use disorder seeking treatment, direct access to a live person who can answer questions regarding referrals and various treatment programs. the helpline will also follow-up on treatment compliance and offer support and motivational techniques for these individuals to stay engaged in treatment 2. test if the helpline is a resourceful tool for patients with new onset of pain or chronic pain being prescribed opioids. the opioid helpline will provide these individuals the necessary educational materials on managing pain safely while avoiding misuse. it will offer free imagery guided meditation and other non-pharmacological tools to help with pain management. 3. test if providers find the opioid helpline helpful and resourceful for their practice and are willing to refer patients to the helpline.

Eligibility criteria:
inclusion criteria: participant criteria: 1. age greater than or equal to 18 years. 2. a formal diagnosis of opioid use disorder (oud) by a health care provider or 3. if no formal diagnosis of oud, having a self-reported concern with opioid use or addiction. 4. an individual seeking to reduce opioid use. 5. an individual concerned about opioids prescribed for management of new-onset pain or chronic pain. provider criteria: 1. university of virginia: providers of any specialties within va including dentists that prescribes opioids. 2. county of wise: providers of any specialties including dentists that prescribes opioids. exclusion criteria: participant criteria: 1. individuals under 18 years of age. 2. individuals seeking treatment for non-opioid substance use disorders 3. individuals who have no pain issues 4. individuals located outside of virginia. provider criteria: providers outside the designated regions.

Keywords: opioid dependence pain management
evaluating a treatment effect in patients with fbss using an electronic nose: a pilot study

Conditions: Failed Back Surgery Syndrome

Summary: this study is an experimental single-center pilot study investigating volatile organic compounds patterns in exhaled breath during on and off states of scs, in patient with failed back surgery syndrome.


Eligibility criteria:
inclusion criteria: * diagnosis of fbss (failed conservative treatments for pain including but not limited to pharmacological therapy and physical therapy) and currently being treated with spinal cord stimulation. exclusion criteria: * patients with a diagnosis of cancer. * patients with major psychiatric problems. * patients with an underlying respiratory disease.
study of atorvastatin dose dependent reduction of proteinuria

Conditions: Chronic Kidney Disease

Summary: randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.


Eligibility criteria:
inclusion criteria: * age of 18 and over * stage 3 or 4 chronic kidney disease (modified mdrd) * proteinuria of \> 1g/d on acei and/or arb, or proteinuria of \> 1g/d with intolerance or contraindication to acei and/or arb * blood pressure \< 130/80 mmhg or \< 140/90 mmhg in patients with five or more antihypertensive drugs * stable renal function exclusion criteria: * rapid progression of renal failure * immunosuppressive therapy within the past 3 months * need a renal replacement therapy within 8 months * definite history of chronic liver disease, or abnormal liver function * evidence of active inflammatory muscle disease * definite previous adverse reaction to a statin * concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin) * child bearing potential * known to be poorly compliant with clinic visits or prescribed medication

Keywords: chronic kidney disease
study evaluating the pronostic value of vascular refilling rate on mortality in chronic kidney disease patients on dialysis

Conditions: Chronic Kidney Diseases

Summary: aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (stage 5d) during an observational period of 3 years: * the prognostic value of vascular refilling rate on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number * the prognostic value of interdialytic weight gain on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number * the prognostic value of perdialytic weight loss on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number.


Eligibility criteria:
inclusion criteria: * chronic kidney disease patient on dialysis (stage 5d) since at least september 2017 (3 months prior to study start date) * anuric patient exclusion criteria: - chronic kidney disease patient on dialysis with residual kidney function

Keywords: chronic kidney disease patient on dialysis (stage 5d) extracorporeal purification sodium
quality of sleep of patients with predominant central sleep apnea syndrome(sas) whose ef > 45% treated by asv

Conditions: Central Sleep Apnea Syndrome in Patients Whose EF is Above 45 Percent

Summary: the main goal of this french multicenter observational cohort study is to prospectively collect data assessing the impact of the adaptative servo-ventilation treatment on the quality of sleep of patients with central or combined sleep apnea syndrome (sas) out of heart failure (hf) with altered ejection fraction, with a predominant central sas.


Eligibility criteria:
inclusion criteria: * patient over 18 years * naive patient to treatment with positive pressure with ahic \> 15 requiring the establishment of an asv to a central or combined sas without any systolic hf (lvef ≤ 45%) with predominant central sas. * or patient with a predominant obstructive sas ( ≤ 50% central event ) whose continuous positive airway pressure treatment (cpap) does not allow adequate control of the central events: treated for at least 1 month cpap with a residual central apnea hypopnea index greater than or equal to 10 events per hour (ahi global\> 15, which ahic ≥ 10) pressure to control obstructive events ( iaho \<5 ) controlled by polygraphy or polysomnography with a pressure test \<10 cm h2o. * before inclusion, for patients who have previously been treated with cpap, a psg diagnosis will be made after a period of wash-out of cpap of a 1-week period. * patient affiliated to the national social security (beneficiary or assignee ). * patient being aware of the information form and signed informed consent. exclusion criteria: * patients with against -indication for the use of asv : * history of massive epistaxis. * diseases related to barotrauma particularly pneumothorax and pneumo- mediastinum. * suspicions of meningeal gaps or trauma history of the prior stage of the skull base. * shortness of breath or hypercapnia deemed incompatible by the doctor with the asv treatment. * patients with predominant obstructive sleep apnea (osa) (\> 85% obstructive events ). * standardized central sas by the continuous positive airway pressure * patients with a diagnosis of systolic heart failure (lvef ≤45 %) with a predominant central sas ( \> 50% central events ). * person deprived of liberty by judicial or administrative decision, person under a legal protection measure (pregnant or lactating women, patients under guardianship) * lack of signature for the information form and the informed consent form.